As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
Content to be used in accordance with local CPO guidelines
4-Year update of phase 2 ELARA Trial: Clinical outcomes of tisagenlecleucel in patients (PTS) with high-risk relapsed/refractory follicular lymphoma (R/R FL)
Catherine Thieblemont*, Martin Dreyling, Michael Dickinson, Joaquin Martínez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter Riedell, P. Joy Ho, Perez Simon Josè Antonio, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés Ferreri, Takanori Teshima, Piers Patten, Joseph McGuirk, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Davide Germano, Roberto Ramos, Pei Hsu, Stephen Schuster, Nathan Fowler
Poster presentation #PS2150
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
Pregnancy and infant outcomes post–CD19-D directed CAR-T therapy: Tisagenlecleucel (tisa-cel) and/or huCAR19 (CTL119)
Marianne Ifversen*, Stephan Grupp, Dana Salzberg, Julie Wolfson, Mara Constantinescu, Andrea Jegerlehner, Rakesh Awasthi, Jeniffer Willert, Noelle Frey, Andy Chen
Poster presentation #PS2158
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
Tisagenlecleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma: An updated matching-adjusted indirect comparison (MAIC) analysis after 3-year follow-up data
Catherine Thieblemont*, Stephen Schuster, Hongbo Yang, Cheryl Xiang, Yuehan Zhang, Roberto Ramos, Darragh O’Donovan, Etienne Jousseaume, Martin Dreyling, Nathan Fowler
Publication only #PB3482
Rapcabtagene autoleucel (YTB323) in patients with relapsed/refractory diffuse large B-cell lymphoma: A phase II trial clinical update
Mi Kwon*, Peter Riedell, Ian W. Flinn, Michael Dickinson, Carlos Solano Vercet, Ulrich Jeager, Javier Briones-Meijide, Koji Kato, Shaun Fleming, Emmanuel Bachy, Alessandro Rambaldi, Leyla Shune, Nirav N Shah, Didier Blaise, Matthew Frigault, Aravind Ramakrishnan, Anne Yang, David Pearson, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
Poster presentation #PF1152
Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST
First-in-human study of asciminib (ASC) monotherapy in adults with relapsed/refractory (R/R) philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Michael Mauro*, Hironobu Minami, Moshe Talpaz, Srinivas Tantravahi, Maria Gómez-Garcia de Soria, Massimo Breccia, Michael Heinrich, Daniel J. DeAngelo, Jorge Cortes, Koji Sasaki, Yeow Tee Goh, Shruti Kapoor, Andrea Damon, Meng Cao, Haneen Shalabi, Delphine Rea, Fabian Lang
Oral presentation #S119
Coral-7 | Friday, June 13, 2025 | 18:00 – 18:15 CEST
Retrospective analysis of efficacy and safety outcomes in patients with primary and secondary myelofibrosis treated with ruxolitinib: JUMP study
Haifa Kathrin Al-Ali*, Silvia Zaoli, Gabriele Gut, Saadia Iftikhar, Marilisa Neri, Severine Peyrard, Ana Rita Ferreira, Francesca Palandri
Poster presentation #PS1831
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naive patients with myelofibrosis: 72-Week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study
Alessandro Vannucchi*, Raajit Rampal, Dominik Chraniuk, Sebastian Grosicki, Elisabetta Abruzzese, Sung-Eun Lee, Alessandro Lucchesi, Aaron Gerds, Stephen Oh, Andrea Patriarca, Alberto Álvarez Larrán, David Lavie, Vikas Gupta, Andrew Kuykendall, Prithviraj Bose, Moshe Talpaz, Francesca Palandri, Ruben Mesa, Jean-Jacques Kiladjian, Monika Wroclawska, Qing Li, Harald Maier, John Mascarenhas, Claire Harrison
Oral presentation #S223
Coral-7 | Thursday, June 12, 2025 | 17:45 – 18:00 CEST
Primary results STIMULUS-AML1: A large, international, phase II study of sabatolimab combined with azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia (AML) patients (PTS)
Amer M. Zeidan*, Tibor Kovacsovics, Adriano Venditti, Gabriela Rodriguez Macias, Andre Schuh, David Sanford, Uwe Platzbecker, Hee-Je Kim, Jörg Westermann, Vivek Shenoy, Jiaying Lyu, Hans D. Menssen, Ludmila Lupu, Meryem Ktiouet Dawson, Jordi Esteve Reyner
Poster presentation #PS1483
Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
